The DOI matches its Crossref record; 48 of the 49 references it cites were found in a registry or an index.
Ibrutinib is an irreversible molecular inhibitor of ITK driving a Th1-selective pressure in T lymphocytes
Open accessAbstract
Given its critical role in T-cell signaling, interleukin-2-inducible kinase (ITK) is an appealing therapeutic target that can contribute to the pathogenesis of certain infectious, autoimmune, and neoplastic diseases. Ablation of ITK subverts Th2 immunity, thereby potentiating Th1-based immune responses. While small-molecule ITK inhibitors have been identified, none have demonstrated clinical utility. Ibrutinib is a confirmed irreversible inhibitor of Bruton tyrosine kinase (BTK) with outstanding clinical activity and tolerability in B-cell malignancies. Significant homology between BTK and ITK alongside in silico docking studies support ibrutinib as an immunomodulatory inhibitor of both ITK and BTK. Our comprehensive molecular and phenotypic analysis confirms ITK as an irreversible T-cell target of ibrutinib. Using ibrutinib clinical trial samples along with well-characterized neoplastic (chronic lymphocytic leukemia), parasitic infection (Leishmania major), and infectious disease (Listeria monocytogenes) models, we establish ibrutinib as a clinically relevant and physiologically potent ITK inhibitor with broad therapeutic utility. This trial was registered at www.clinicaltrials.gov as #NCT01105247 and #NCT01217749.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Although ibrutinib inhibits other similar kinases that contain C481, including ITK and BLK,7,22”
From Resistance Mechanisms for the Bruton's Tyrosine Kinase Inhibitor Ibrutinib (2014) · cites this paper as [22]
Experimental — accuracy not yet measuredThe check wasn’t confident either way, so it gives no verdict — never disputed.
In the citing paper
“At relapse, none of the patients had mutations in other kinases containing a cysteine residue homologous to C481 in BTK that are irreversibly inhibited by ibrutinib”
From Resistance Mechanisms for the Bruton's Tyrosine Kinase Inhibitor Ibrutinib (2014) · cites this paper as [22]
Experimental — accuracy not yet measuredThe check wasn’t confident either way, so it gives no verdict — never disputed.
In the citing paper
“mutations have not been observed in these other targets, findings that suggest that BTK is its critical target.”
From Resistance Mechanisms for the Bruton's Tyrosine Kinase Inhibitor Ibrutinib (2014) · cites this paper as [22]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Honigberg, L. A., Smith, A. M., Sirisawad, M., Verner, E., Loury, D., Chang, B., Li, S., Pan, Z., Thamm, D. H., Miller, R. A., et al. (2010) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1004594107 · Cited by 1,561
Self-citationAdvani, R. H., Buggy, J. J., Sharman, J. P., Smith, S. M., Boyd, T. E., Grant, B., Kolibaba, K. S., Furman, R. R., Rodriguez, S., Chang, B. Y., et al. (2013) · Journal of Clinical Oncology · doi:10.1200/jco.2012.42.7906 · Cited by 1,128 · cited 1×
“Irreversible ITK binding, ITK signal inhibition, and Th1-skewed cytokine patterns were also identified in CLL patients treated with ibrutinib in 2 clinical trials.(37,38) These findings were validated using a well-established mouse model of cutaneous leishmaniasis, and further clinical relevance was demonstrated using…”
BackgroundSelf-citationHerman, S. E. M., Gordon, A. L., Hertlein, E., Ramanunni, A., Zhang, X., Jaglowski, S., Flynn, J., Jones, J., Blum, K. A., Buggy, J. J., et al. (2011) · Blood · doi:10.1182/blood-2011-01-328484 · Cited by 807
Self-citationLong-term Outcome of 525 Patients With Mycosis Fungoides and Sézary Syndrome
Kim, Y. H., Liu, H. L., Mraz‐Gernhard, S., Varghese, A., & Hoppe, R. T. (2003) · Archives of Dermatology · doi:10.1001/archderm.139.7.857 · Cited by 652
Ramsay, A. G., Johnson, A. J., Lee, A. M., Görgün, G., Dieu, R. L., Blum, W. G., Byrd, J. C., & Gribben, J. G. (2008) · Journal of Clinical Investigation · doi:10.1172/jci35017 · Cited by 619
Self-citationMarks, D. I., Paietta, E. M., Moorman, A. V., Richards, S. M., Buck, G. A. N., Dewald, G. W., Ferrando, A. A., Fielding, A. K., Goldstone, A. H., Ketterling, R. P., et al. (2009) · Blood · doi:10.1182/blood-2009-08-231217 · Cited by 420
The B-cell receptor signaling pathway as a therapeutic target in CLL
Woyach, J. A., Johnson, A. J., & Byrd, J. C. (2012) · Blood · doi:10.1182/blood-2012-02-362624 · Cited by 412
Self-citationRequirement for Tec Kinases Rlk and Itk in T Cell Receptor Signaling and Immunity
Schaeffer, E. M., Debnath, J., Yap, G. S., McVicar, D. W., Liao, X. C., Littman, D. R., Sher, A., VARMUS, H. E., Lenardo, M. J., & Schwartzberg, P. L. (1999) · Science · doi:10.1126/science.284.5414.638 · Cited by 398
TEC FAMILY KINASES IN T LYMPHOCYTE DEVELOPMENT AND FUNCTION
Berg, L. J., Finkelstein, L. D., Lucas, J. A., & Schwartzberg, P. L. (2004) · Annual Review of Immunology · doi:10.1146/annurev.immunol.22.012703.104743 · Cited by 341
Liu, K., Bunnell, S. C., Gurniak, C. B., & Berg, L. J. (1998) · The Journal of Experimental Medicine · doi:10.1084/jem.187.10.1721 · Cited by 337
Cited by
Sorted by citations
Items 101–200 of 813
Advancement in leishmaniasis diagnosis and therapeutics: An update
Kumari, D., Perveen, S., Sharma, R., & Singh, K. (2021) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2021.174436 · Cited by 92
BTK signaling—a crucial link in the pathophysiology of chronic spontaneous urticaria
Bernstein, J. A., Maurer, M., & Saini, S. S. (2023) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2023.12.008 · Cited by 92
Wiestner, A. U. (2015) · Haematologica · doi:10.3324/haematol.2014.119123 · Cited by 92
Targeting the tumor microenvironment in chronic lymphocytic leukemia
Svanberg, R., Janum, S., Patten, P., Ramsay, A. G., & Niemann, C. U. (2021) · Haematologica · doi:10.3324/haematol.2020.268037 · Cited by 90
O'Brien, S. M., Furman, R. R., Coutre, S. E., Flinn, I. W., Burger, J. A., Blum, K. A., Sharman, J. P., Wierda, W. G., Jones, J. A., Zhao, W., et al. (2016) · Blood · doi:10.1182/blood.v128.22.233.233 · Cited by 88
Self-citationBefriending the Hostile Tumor Microenvironment in CAR T-Cell Therapy
Lindo, L., Wilkinson, L., & Hay, K. A. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2020.618387 · Cited by 92
Ibrutinib inhibits pre-BCR+ B-cell acute lymphoblastic leukemia progression by targeting BTK and BLK
Kim, E., Hurtz, C., Koehrer, S., Wang, Z., Balasubramanian, S., Chang, B. Y., Müschen, M., Davis, R. E., & Burger, J. A. (2016) · Blood · doi:10.1182/blood-2016-06-722900 · Cited by 88
Self-citationLaw, M. F., Ho, R., Cheung, C. K. M., Tam, L. H. P., Ma, K., So, C.-Y., Ip, B. Y. M., So, J., Lai, J. W.-Y., Ng, J., et al. (2016) · World Journal of Gastroenterology · doi:10.3748/wjg.v22.i28.6484 · Cited by 87
B Cells in Chronic Graft-versus-Host Disease
Sarantopoulos, S., Blazar, B. R., Cutler, C. S., & Ritz, J. (2014) · Transplantation and Cellular Therapy · doi:10.1016/j.bbmt.2014.10.029 · Cited by 87
Haematological malignancies: at the forefront of immunotherapeutic innovation
Bachireddy, P., Burkhardt, U. E., Rajasagi, M., & Wu, C. J. (2015) · Nature Reviews Cancer · doi:10.1038/nrc3907 · Cited by 85
Pseudokinases: Update on Their Functions and Evaluation as New Drug Targets
Byrne, D. P., Foulkes, D. M., & Eyers, P. A. (2017) · Future Medicinal Chemistry · doi:10.4155/fmc-2016-0207 · Cited by 84
Stock, S., Übelhart, R., Schubert, M., Fan, F., He, B., Hoffmann, J., Wang, L., Wang, S., Gong, W., Neuber, B., et al. (2019) · International Journal of Cancer · doi:10.1002/ijc.32201 · Cited by 82
Role of the IL-2 inducible tyrosine kinase ITK and its inhibitors in disease pathogenesis
Lechner, K., Neurath, M. F., & Weigmann, B. (2020) · Journal of Molecular Medicine · doi:10.1007/s00109-020-01958-z · Cited by 82
Sagiv-Barfi, I., Kohrt, H. E. K., Burckhardt, L., Czerwinski, D. K., & Levy, R. (2015) · Blood · doi:10.1182/blood-2014-08-593137 · Cited by 83
Manne, B. K., Badolia, R., Dangelmaier, C., Eble, J. A., Ellmeier, W., Kahn, M. L., & Kunapuli, S. P. (2015) · Journal of Biological Chemistry · doi:10.1074/jbc.m114.629527 · Cited by 82
Myklebust, J. H., Brody, J., Kohrt, H. E. K., Kolstad, A., Czerwinski, D. K., Wälchli, S., Green, M. R., Trøen, G., Liestøl, K., Beiske, K., et al. (2016) · Blood · doi:10.1182/blood-2016-05-718494 · Cited by 84
Hong, D. S., Rasco, D. W., Veeder, M. H., Luke, J. J., Chandler, J. C., Balmanoukian, A. S., George, T. J., Münster, P. N., Berlin, J. D., Gutierrez, M. E., et al. (2019) · Oncology · doi:10.1159/000500571 · Cited by 81
Fan, F., Yoo, H. J., Stock, S., Wang, L., Liu, Y., Schubert, M., Wang, S., Neuber, B., Hückelhoven‐Krauss, A., Gern, U., et al. (2020) · International Journal of Cancer · doi:10.1002/ijc.33212 · Cited by 82
BTK Inhibitors in Chronic Lymphocytic Leukemia: Biological Activity and Immune Effects
Palma, M., Mulder, T. A., & Österborg, A. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.686768 · Cited by 83
Three US Food and Drug Administration–approved therapies for chronic GVHD
Zeiser, R., & Lee, S. J. (2022) · Blood · doi:10.1182/blood.2021014448 · Cited by 83
Immune checkpoint inhibitors: therapeutic advances in melanoma.
Márquez‐Rodas, I., Cerezuela-Fuentes, P., Soria, A., Berrocal, A., Riso, A. A., González‐Cao, M., & Martín‐Algarra, S. (2015) · Europe PMC (PubMed Central) · doi:10.3978/j.issn.2305-5839.2015.10.27 · Cited by 82
Aalipour, A., & Advani, R. H. (2014) · Therapeutic Advances in Hematology · doi:10.1177/2040620714539906 · Cited by 84
Dreger, P., Michallet, M., Bosman, P. V., Dietrich, S., Sobh, M., Boumendil, A., Nagler, A., Scheid, C., Cornelissen, J. J., Niederwieser, D. W., et al. (2018) · Bone Marrow Transplantation · doi:10.1038/s41409-018-0207-4 · Cited by 78
Solman, I. G., Blum, L. K., Hoh, H. Y., Kipps, T. J., Burger, J. A., Barrientos, J. C., O'Brien, S. M., Mulligan, S. P., Kay, N. E., Hillmen, P., et al. (2020) · Leukemia Research · doi:10.1016/j.leukres.2020.106432 · Cited by 81
Self-citationJain, N., Senapati, J., Thakral, B., Ferrajoli, A., Thompson, P. A., Burger, J. A., Basu, S., Kadia, T. M., Daver, N. G., Borthakur, G. M., et al. (2022) · Blood Advances · doi:10.1182/bloodadvances.2022008790 · Cited by 78
Chronic lymphocytic leukemia cells are active participants in microenvironmental cross-talk
van Attekum, M. H. A., Eldering, E., & Kater, A. P. (2017) · Haematologica · doi:10.3324/haematol.2016.142679 · Cited by 81
Qin, J., Johnstone, T. G., Baturevych, A., Hause, R. J., Ragan, S. P., Clouser, C. R., Jones, J. C., Ponce, R. A., Krejsa, C. M., Salmon, R. A., et al. (2020) · Journal of Immunotherapy · doi:10.1097/cji.0000000000000307 · Cited by 79
Self-citationTCR Signal Strength and Antigen Affinity Regulate CD8+ Memory T Cells
Solouki, S., Huang, W., Elmore, J. P., Limper, C., Huang, F., & August, A. (2020) · The Journal of Immunology · doi:10.4049/jimmunol.1901167 · Cited by 82
Ryan, C. E., Sahaf, B., Logan, A. C., O'Brien, S. M., Byrd, J. C., Hillmen, P., Brown, J. R., Dyer, M. J. S., Mato, A. R., Keating, M. J., et al. (2016) · Blood · doi:10.1182/blood-2016-06-715284 · Cited by 77
Self-citationVarikuti, S., Singh, B., Volpedo, G., Ahirwar, D. K., Jha, B. K., Saljoughian, N., Viana, A. G., Verma, C., Hamza, O., Halsey, G., et al. (2020) · British Journal of Cancer · doi:10.1038/s41416-020-0743-8 · Cited by 76
Self-citationTargeted therapies for CLL: Practical issues with the changing treatment paradigm
Jain, N., & O'Brien, S. M. (2015) · Blood Reviews · doi:10.1016/j.blre.2015.12.002 · Cited by 76
B cells in chronic graft-versus-host disease
McManigle, W. C., Youssef, A., & Sarantopoulos, S. (2019) · Human Immunology · doi:10.1016/j.humimm.2019.03.003 · Cited by 81
Host-Directed Drug Therapies for Neglected Tropical Diseases Caused by Protozoan Parasites
Varikuti, S., Jha, B. K., Volpedo, G., Ryan, N. M., Halsey, G., Hamza, O., McGwire, B. S., & Satoskar, A. R. (2018) · Frontiers in Microbiology · doi:10.3389/fmicb.2018.02655 · Cited by 76
Self-citationA three‐signal model of T ‐cell lymphoma pathogenesis
Wilcox, R. A. (2015) · American Journal of Hematology · doi:10.1002/ajh.24203 · Cited by 77
Hilal, T., Gea‐Banacloche, J., & Leis, J. F. (2018) · Blood Reviews · doi:10.1016/j.blre.2018.03.004 · Cited by 74
Lampson, B. L., & Brown, J. R. (2018) · Expert Review of Hematology · doi:10.1080/17474086.2018.1435268 · Cited by 74
From Biology to Therapy: The CLL Success Story
Yosifov, D. Y., Wolf, C. H., Stilgenbauer, S., & Mertens, D. (2019) · HemaSphere · doi:10.1097/hs9.0000000000000175 · Cited by 76
The landscape of new drugs in lymphoma
Younes, A., Ansell, S. M., Fowler, N. H., Wilson, W. H., de Vos, S., Seymour, J. F., Advani, R. H., Forero, A., Morschhauser, F., Kersten, M. J., et al. (2016) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2016.205 · Cited by 73
Ibrutinib combinations in CLL therapy: scientific rationale and clinical results
Timofeeva, N., & Gandhi, V. V. (2021) · Blood Cancer Journal · doi:10.1038/s41408-021-00467-7 · Cited by 70
Zhang, J., Liao, D., Chen, R., Zhu, F., Ma, Y., Gao, L., Qu, G., Cui, C., Sun, Z., Lei, X., et al. (2022) · Angewandte Chemie International Edition · doi:10.1002/anie.202201908 · Cited by 69
PI3K Signaling in Normal B Cells and Chronic Lymphocytic Leukemia (CLL)
Okkenhaug, K., & Burger, J. A. (2015) · Current topics in microbiology and immunology · doi:10.1007/82_2015_484 · Cited by 70
Borge, M., Almejún, M. B., Podaza, E., Colado, A., Grecco, H. F., Cabrejo, M., Bezares, R. F., Giordano, M., & Gamberale, R. (2015) · Haematologica · doi:10.3324/haematol.2014.119669 · Cited by 69
Ren, L., Campbell, A. R., Fang, H., Gautam, S., Elavazhagan, S., Fatehchand, K., Mehta, P., Stiff, A. R., Reader, B. F., Mo, X. M., et al. (2015) · Journal of Biological Chemistry · doi:10.1074/jbc.m115.687251 · Cited by 69
Self-citationImmune Dysfunctions and Immune-Based Therapeutic Interventions in Chronic Lymphocytic Leukemia
Griggio, V., Perutelli, F., Salvetti, C., Boccellato, E., Boccadoro, M., Vitale, C., & Coscia, M. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.594556 · Cited by 71
Leclercq-Cohen, G., Steinhoff, N., Haegel, H., Marco, D. D., Bacac, M., & Klein, C. (2022) · OncoImmunology · doi:10.1080/2162402x.2022.2083479 · Cited by 70
Signaling pathway and dysregulation of PD1 and its ligands in lymphoid malignancies
Xia, Y., Medeiros, L. J., & Young, K. H. (2015) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2015.09.002 · Cited by 68
Ibrutinib inhibits SDF1/CXCR4 mediated migration in AML
Zaitseva, L., Murray, M. Y., Shafat, M. S., Lawes, M. J., MacEwan, D. J., Bowles, K. M., & Rushworth, S. A. (2014) · Oncotarget · doi:10.18632/oncotarget.2479 · Cited by 69
Miklos, D. B., Zaid, M. I. A., Cooney, J. P., Albring, J. C., Flowers, M. E. D., Skarbnik, A. P. Z., Yakoub‐Agha, I., Ko, B., Bruno, B., Waller, E. K., et al. (2023) · Journal of Clinical Oncology · doi:10.1200/jco.22.00509 · Cited by 67
The importance of B cell receptor isotypes and stereotypes in chronic lymphocytic leukemia
ten Hacken, E., Gounari, M., Ghia, P., & Burger, J. A. (2018) · Leukemia · doi:10.1038/s41375-018-0303-x · Cited by 72
Wang, M., Liu, Y., Cheng, Y., Wei, Y., & Wei, X. (2019) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2018.12.002 · Cited by 66
Yeomans, A., Thirdborough, S. M., Valle‐Argos, B., Linley, A. J., Krysov, S. V., Sánchéz‐Hidalgo, M., Leonard, E., Ishfaq, M., Wagner, S. D., Willis, A. E., et al. (2015) · Blood · doi:10.1182/blood-2015-07-660969 · Cited by 69
Reiff, S. D., Muhowski, E. M., Guinn, D., Lehman, A., Fabian, C. A., Cheney, C. M., Mantel, R., Smith, L., Johnson, A. J., Young, W. B., et al. (2018) · Blood · doi:10.1182/blood-2017-10-809020 · Cited by 66
Self-citationState-of-the-art for CAR T-cell therapy for chronic lymphocytic leukemia in 2019
Lemal, R., & Tournilhac, O. (2019) · Journal for ImmunoTherapy of Cancer · doi:10.1186/s40425-019-0686-x · Cited by 67
Xia, S., Liu, X., Cao, X., & Xu, S. (2019) · Cellular and Molecular Immunology · doi:10.1038/s41423-019-0270-9 · Cited by 66
Thompson, P. A., & Burger, J. A. (2017) · Expert Opinion on Investigational Drugs · doi:10.1080/13543784.2018.1404027 · Cited by 66
Jain, M. D., & Davila, M. L. (2017) · Stem Cells · doi:10.1002/stem.2715 · Cited by 67
Lavik, A. R., Zhong, F., Chang, M.-J., Greenberg, E. F., Choudhary, Y., Smith, M. R., McColl, K. S., Pink, J. J., Reu, F. J., Matsuyama, S., et al. (2015) · Oncotarget · doi:10.18632/oncotarget.4489 · Cited by 65
T Cells in Chronic Lymphocytic Leukemia: A Two-Edged Sword
Vlachonikola, E., Σταματόπουλος, Κ., & Chatzidimitriou, A. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2020.612244 · Cited by 65
Novel strategies to manage CAR-T cell toxicity
Mulvey, A., Trueb, L., Coukos, G., & Arber, C. (2025) · Nature Reviews Drug Discovery · doi:10.1038/s41573-024-01100-5 · Cited by 69
Hamasy, A., Wang, Q., Blomberg, K. E. M., Mohammad, D. K., Yu, L., Vihinen, M., Berglöf, A., & Smith, C. I. E. (2017) · Leukemia · doi:10.1038/leu.2016.153 · Cited by 62
CAR T-Cell Therapy: The Role of Physical Barriers and Immunosuppression in Lymphoma
Enblad, G., Karlsson, H., & Loskog, A. (2015) · Human Gene Therapy · doi:10.1089/hum.2015.054 · Cited by 65
Sharman, J. P., Farber, C. M., Mahadevan, D., Schreeder, M. T., Brooks, H. D., Kolibaba, K. S., Fanning, S. R., Klein, L. M., Greenwald, D. R., Sportelli, P., et al. (2016) · British Journal of Haematology · doi:10.1111/bjh.14447 · Cited by 63
Self-citationHow does lenalidomide target the chronic lymphocytic leukemia microenvironment?
Kater, A. P., Tonino, S. H., Egle, A., & Ramsay, A. G. (2014) · Blood · doi:10.1182/blood-2014-05-578286 · Cited by 61
Maffei, R., Fiorcari, S., Martinelli, S., Potenza, L., Luppi, M., & Marasca, R. (2015) · Journal of Hematology & Oncology · doi:10.1186/s13045-015-0157-x · Cited by 63
Montillo, M., O'Brien, S. M., Tedeschi, A., Byrd, J. C., Dearden, C. E., Gill, D. S., Brown, J. R., Barrientos, J. C., Mulligan, S. P., Furman, R. R., et al. (2017) · Blood Cancer Journal · doi:10.1038/bcj.2017.5 · Cited by 61
Self-citationHerrera, A. F., Goy, A. H., Mehta, A., Ramchandren, R., Pagel, J. M., Svoboda, J., Guan, S., Hill, J. S., Kwei, K. A., Liu, E. A., et al. (2019) · American Journal of Hematology · doi:10.1002/ajh.25659 · Cited by 60
Westin, J. R., Davis, R. E., Feng, L., Hagemeister, F. B., Steiner, R. E., Lee, H. J., Fayad, L., Nastoupil, L. J., Ahmed, S., Rodriguez, M. A., et al. (2022) · Journal of Clinical Oncology · doi:10.1200/jco.22.00597 · Cited by 60
Harrington, B. K., Gardner, H. L., Izumi, R. E., Hamdy, A., Rothbaum, W. M., Coombes, K. R., Covey, T. M., Kaptein, A., Gulrajani, M., van Lith, B., et al. (2016) · PLoS ONE · doi:10.1371/journal.pone.0159607 · Cited by 59
Self-citationWang, T., Lu, Y., Polk, A., Chowdhury, P., Zamalloa, C. M., Fujiwara, H., Suemori, K., Beyersdorf, N., Hristov, A. C., Lim, M. S., et al. (2016) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-16-1996 · Cited by 59
How will B-cell-receptor–targeted therapies change future CLL therapy?
Jones, J. A., & Byrd, J. C. (2014) · Blood · doi:10.1182/blood-2013-09-453092 · Cited by 58
Self-citationGood, Z., Borges, L., Gonzalez, N. V., Sahaf, B., Samusik, N., Tibshirani, R. J., Nolan, G. P., & Bendall, S. C. (2019) · Nature Biotechnology · doi:10.1038/s41587-019-0033-2 · Cited by 58
Huemer, F., Leisch, M., Geisberger, R., Melchardt, T., Rinnerthaler, G., Zaborsky, N., & Greil, R. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21082856 · Cited by 60
Flinsenberg, T. W. H., Tromedjo, C. C., Hu, N., Liu, Y., Guo, Y., Thia, K. Y. T., Noori, T., Song, X., Aw Yeang, H. X., Tantalo, D. G., et al. (2020) · Haematologica · doi:10.3324/haematol.2019.220590 · Cited by 56
Novel Indications for Bruton’s Tyrosine Kinase Inhibitors, beyond Hematological Malignancies
Campbell, R., Chong, G., & Hawkes, E. A. (2018) · Journal of Clinical Medicine · doi:10.3390/jcm7040062 · Cited by 56
Ferrer, G., Jung, B., Chiu, P. Y., Aslam, R., Palacios, F., Mazzarello, A. N., Vergani, S., Bagnara, D., Chen, S., Yancopoulos, S., et al. (2021) · Leukemia · doi:10.1038/s41375-021-01249-7 · Cited by 56
Zou, Y., Zhu, H., Li, X., Xia, Y., Miao, K., Zhao, S., Wu, Y., Wang, L., Xu, W., & Li, J. (2019) · Hematological Oncology · doi:10.1002/hon.2667 · Cited by 56
Tadmor, T., Welslau, M., & Hus, I. (2017) · Expert Review of Hematology · doi:10.1080/17474086.2018.1407645 · Cited by 55
Harnessing the Effects of BTKi on T Cells for Effective Immunotherapy against CLL
Mhibik, M., Wiestner, A. U., & Sun, C. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms21010068 · Cited by 57
Zhu, S., Gokhale, S., Jung, J., Spirollari, E., Tsai, J., Arceo, J., Wu, B. W., Victor, E., & Xie, P. (2021) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2021.727531 · Cited by 54
Improving CLL Vγ9Vδ2-T–cell fitness for cellular therapy by ex vivo activation and ibrutinib
de Weerdt, I., Hofland, T., Lameris, R., Endstra, S., Jongejan, A., Moerland, P. D., de Bruin, R. C. G., Remmerswaal, E. B. M., ten Berge, I. J. M., Liu, N., et al. (2018) · Blood · doi:10.1182/blood-2017-12-822569 · Cited by 54
Giacopelli, B., Wang, M., Sher, A. C., Wu, Y.-Z., Schultz, A. R., Schmutz, M., Blachly, J. S., Eisfeld, A., Mundy-Bosse, B. L., Vosberg, S., et al. (2021) · Genome Research · doi:10.1101/gr.269233.120 · Cited by 58
Self-citationMurray, M. Y., Zaitseva, L., Auger, M. J., Craig, J. I. O., MacEwan, D. J., Rushworth, S. A., & Bowles, K. M. (2015) · Cell Cycle · doi:10.1080/15384101.2014.998067 · Cited by 55
Hampel, P. J., Larson, M. C., Kabat, B., Call, T. G., Ding, W., Kenderian, S. S., Bowen, D. A., Boysen, J. C., Schwager, S. M., Leis, J. F., et al. (2018) · British Journal of Haematology · doi:10.1111/bjh.15545 · Cited by 53
Dong, S., Harrington, B. K., Hu, E. Y., Greene, J. T., Lehman, A. M., Tran, M., Wasmuth, R. L., Long, M., Muthusamy, N., Brown, J. R., et al. (2018) · Journal of Clinical Investigation · doi:10.1172/jci99386 · Cited by 52
Self-citationBeyond bystanders: Myeloid cells in chronic lymphocytic leukemia
Hanna, B. S., Öztürk, S., & Seiffert, M. (2017) · Molecular Immunology · doi:10.1016/j.molimm.2017.11.014 · Cited by 52
Immunomodulation and Immune Reconstitution in Chronic Lymphocytic Leukemia
Riches, J. C., & Gribben, J. G. (2014) · Seminars in Hematology · doi:10.1053/j.seminhematol.2014.05.006 · Cited by 52
Immune checkpoint blockade: Releasing the brake towards hematological malignancies
Xia, Y., Medeiros, L. J., & Young, K. H. (2015) · Blood Reviews · doi:10.1016/j.blre.2015.11.003 · Cited by 53
Zhong, Y., Dong, S., Strattan, E., Ren, L., Butchar, J. P., Thornton, K., Mishra, A., Porcu, P., Bradshaw, J. M., Bisconte, A. R., et al. (2015) · Journal of Biological Chemistry · doi:10.1074/jbc.m114.614891 · Cited by 53
Self-citationBose, P., Gandhi, V. V., & Keating, M. J. (2016) · Expert Opinion on Drug Metabolism & Toxicology · doi:10.1080/17425255.2016.1239717 · Cited by 52
Berg, M. H., Rincon, S. V. D., & Miller, W. H. (2022) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2021-003551 · Cited by 53
Chae, Y. K., Galvez, C., Anker, J. F., Iams, W. T., & Bhave, M. A. (2017) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2017.12.004 · Cited by 50
Addition of BTK inhibitor orelabrutinib to rituximab improved anti-tumor effects in B cell lymphoma
Yu, H., Wang, X., Li, J., Ye, Y., Wang, D., Fang, W., Mi, L., Ding, N., Wang, X., Song, Y., et al. (2021) · Molecular Therapy — Oncolytics · doi:10.1016/j.omto.2021.03.015 · Cited by 49
Marofi, F., Rahman, H. S., Achmad, M. H., Sergeevna, K. N., Suksatan, W., Abdelbasset, W. K., Mikhailova, M. V., Shomali, N., Yazdanifar, M., Hassanzadeh, A., et al. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.681984 · Cited by 48
RetractedNew Strategies in Chronic Lymphocytic Leukemia: Shifting Treatment Paradigms
Awan, F. T., & Byrd, J. C. (2014) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-14-1889 · Cited by 48
Self-citationShree, T., Shankar, V., Lohmeyer, J. J. K., Czerwinski, D. K., Schroers‐Martin, J. G., Rodriguez, G. M., Beygi, S., Kanegai, A. M., Corbelli, K. S., Gabriel, E., et al. (2022) · Blood Cancer Discovery · doi:10.1158/2643-3230.bcd-21-0222 · Cited by 47
Activity of lenalidomide in mantle cell lymphoma can be explained by NK cell‐mediated cytotoxicity
Hagner, P. R., Chiu, H., Ortiz, M., Apollonio, B., Wang, M., Couto, S. S., Waldman, M. F., Flynt, E., Ramsay, A. G., Trotter, M. W. B., et al. (2017) · British Journal of Haematology · doi:10.1111/bjh.14866 · Cited by 48
Satterthwaite, A. B. (2018) · Frontiers in Immunology · doi:10.3389/fimmu.2017.01986 · Cited by 47
Targeting Bruton’s Tyrosine Kinase Across B-Cell Malignancies
da Cunha‐Bang, C., & Niemann, C. U. (2018) · Drugs · doi:10.1007/s40265-018-1003-6 · Cited by 47
Ansell, S. M., & Lin, Y. (2020) · Journal of Clinical Investigation · doi:10.1172/jci129206 · Cited by 48
Kinase Inhibition as Treatment for Acute and Chronic Graft-Versus-Host Disease
Braun, L. M., & Zeiser, R. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.760199 · Cited by 48
Metadata
- Authors
- Dubovsky, J. A., Beckwith, K. A., Natarajan, G., Woyach, J. A., Jaglowski, S., Zhong, Y., Hessler, J. D., Liu, T.-M., Chang, B. Y., Larkin, K. M., Stefanovski, M. R., Chappell, D. L., Frissora, F. W., Smith, L. L., Smucker, K. A., Flynn, J. M., Jones, J. A., Andritsos, L. A., Maddocks, K., Lehman, A. M., Furman, R., Sharman, J., Mishra, A., Caligiuri, M. A., Satoskar, A. R., Buggy, J. J., Muthusamy, N., Johnson, A. J., & Byrd, J. C.
- Affiliations
- Department of Internal Medicine, Division of Hematology,
- The Ohio State University (US)
- Pharmacyclics (United States) (US)
- Weill Cornell Medicine (US)
- Willamette Valley Cancer Institute and Research Center (US)
- Department of Pathology, and
- ORCID
- Beckwith, Kyle A.
- Natarajan, Gayathri
- Woyach, Jennifer A.
- Jaglowski, Samantha
- Chang, Betty Y.
- Chappell, Danielle L.
- Smith, Lisa L.
- Flynn, Joseph M.
- Jones, Jeffrey A.
- Andritsos, Leslie A.
- Maddocks, Kami
- Furman, Richard
- Sharman, Jeff
- Mishra, Anjali
- Caligiuri, Michael A.
- Satoskar, Abhay R.
- Muthusamy, Natarajan
- Johnson, Amy J.
- Byrd, John C.
- Venue
- Blood
- Publisher
- American Society of Hematology
- Published
- 2013-10-10
- Volume
- 122
- Issue
- 15
- Pages
- 2539-2549
- ISSN
- 0006-4971 (ISSN-L)
- 1528-0020
- PMC
- PMC3795457
- OpenAlex
- W2089103836
- Cited by
- 810
- References
- 49
- Citations by year
- 2026: 30 · 2025: 43 · 2024: 55 · 2023: 51 · 2022: 70 · 2021: 98 · 2020: 68 · 2019: 71 · 2018: 71 · 2017: 70 · 2016: 65 · 2015: 67 · 2014: 43 · 2013: 5
- FWCI
- 29.54
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- Blood (publishedVersion)
- Europe PMC (PubMed Central) (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Funders
- National Institutes of Health (4p01ca081534-16)
- National Cancer Institute (P01CA095426, P50CA140158, T32CA009338, 5 T32 CA009338-33-03, P30CA016058, K12CA133250, P01-CA-081534)
- Topics
- Health Sciences › Medicine › Hematology › Chronic Lymphocytic Leukemia Research
- Life Sciences › Immunology and Microbiology › Immunology › T-cell and B-cell Immunology
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Protein Degradation and Inhibitors
- Keywords
- ibrutinib, irreversible kinase inhibitors, Bruton's tyrosine kinase, T cell signaling, Th1 response, Th2 immune response, chronic lymphocytic leukemia, Leishmania major, Listeria monocytogenes, immunomodulation
- MeSH terms
- Adenine, Animals, Disease Models, Animal, Enzyme Inhibitors, Humans, Leukemia, Listeriosis, Lymphocyte Activation, Piperidines, Protein-Tyrosine Kinases, Pyrazoles, Pyrimidines, Leishmaniasis, Cutaneous, CD8-Positive T-Lymphocytes, Th1 Cells, Th2 Cells, Jurkat Cells, Mice, Primary Cell Culture
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
